Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Paul Clark

Neurological Surgery Birmingham, AL Medical Doctor

NPI 1619388659 CMS profile 2789021

800 Saint Vincents Dr Ste 700, Ste 700, Birmingham, AL 35205

Open in the dashboard

General payments

$4,718

88 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Paul Clark of Birmingham, AL is reported in the CMS Open Payments database as having received $4,718 across 88 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 57th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $811 21
2024 General $1,622 19
2023 General $397 9
2022 General $799 19
2021 General $1,089 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Clark
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Paul Clark were reported at $811. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Paul Clark Neurological Surgery median Middle half National median
2019 $0 $582 $138–$3,006 $163
2020 $0 $294 $76–$2,174 $114
2021 $1,089 $387 $105–$2,432 $132
2022 $799 $542 $139–$2,989 $149
2023 $397 $534 $145–$2,697 $160
2024 $1,622 $574 $155–$3,046 $164
2025 $811 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $2,957 37 payments
  2. Providence Medical Technology, Inc. $508 8 payments
  3. Spineology Inc. $341 6 payments
  4. DePuy Synthes Sales Inc. $261 7 payments
  5. Orthofix Medical, Inc. $145 10 payments
  6. NuVasive, Inc. $120 4 payments
  7. 4WEB, Inc. $48 2 payments
  8. Cerapedics, Inc. $45 1 payment
  9. KLS-Martin L.P. $41 2 payments
  10. Baxter Healthcare $39 1 payment
  11. Other $214 10 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,425 81 payments
  2. Travel and Lodging $1,293 7 payments
Products named General payments · program years 2021–2025
  1. CD HORIZON SPINAL SYSTEM $1,341 6 payments
  2. PIVOX Oblique Lateral Spinal System $532 9 payments
  3. OPTIMESH EXPANDABLE INTERBODY FUSION SYSTEM $341 6 payments
  4. CD HORIZON $241 2 payments
  5. MAZOR X SYSTEM $203 5 payments
  6. UNID_PASS $167 6 payments
  7. ELEVATE $135 2 payments
  8. VIPER $133 2 payments
  9. Mazor X Stealth Edition $114 1 payment
  10. CATALYFT PL EXPANDABLE INTERBODY SYSTEM $96 2 payments
  11. Other $1,136 44 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

649

Median for Neurosurgery: 83

Drug cost

$5,410

Median for Neurosurgery: $872

Branded share of claims

35.3%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methocarbamol Generic 269 $2,336
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 105 $1,139
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 112 $938
Methylprednisolone Generic 53 $427
Tizanidine Hcl Generic 18 $148
Tramadol Hcl Generic 41 $107
Oxycodone Hcl Generic 11 $97
Gabapentin Generic 13 $92
Acetaminophen-Codeine Acetaminophen With Codeine Brand 12 $92
Cyclobenzaprine Hcl Generic 15 $34

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$67,593

Medicare's payments for the services billed

Medicare patients

146

Average age 72

Services billed

289

75 women, 71 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 41%
Ischemic heart disease 36%
Depression 36%
Chronic kidney disease 32%
Atrial fibrillation 29%
COPD 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

88 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record